PDCD1 and melanoma: Because of the remarkable anecdotal benefit of XP patients to anti-PD-1 ICI, we analyzed XP gene expression as a predictive biomarker for response to anti-PD-1 ICI in two pooled publicly available melanoma cohorts (n = 75) (11, 12).